Author | Kevin Kunzmann


Vaccine Experts Sound Off On Prospects for a COVID-19 Cure

July 31, 2020


The webinar ran well over the hour it had been scheduled for and drew at least 2500 viewers who watched it on average for 71 minutes. And there were 422 questions from the audience afterward.

COVID-19 Vaccine Induces Strong Immune Responses in Clinical Trial

July 20, 2020


The trial, in which 1077 healthy adults in the UK are being assessing for the vaccine comprised of the ChAdOx1 virus for the prevention of SARS-CoV-2, shows enough promise for further assessment.

COVID-19 Vaccine Candidate Induces Immune Response in All Phase 1 Participants

July 15, 2020


New findings show the vaccine candidate mRNA-1273, encoded with a stabilized prefusion SARS-CoV-2 spike protein, induced anti-SARS-CoV-2 immune responses in all of the trial’s participants, without any trial-limiting safety concerns identified.

FDA Issues EUA for Remdesivir After Trio of Studies

April 30, 2020


The US Food and Drug Administration (FDA) has issued an emergency use authorization of the antiviral drug remdesivir for the treatment of patients with coronavirus 2019 (COVID-19).